Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cancer Research Institute Names Six New Investigator Award Winners

06.08.2008
The Cancer Research Institute, a nonprofit charitable organization dedicated to advancing immunology to conquer cancer, announced that the Investigator Award Review Committee of the Institute’s Scientific Advisory Council, with the approval of the Institute’s Board of Trustees, has named six new investigators from its March 2008 application round, awarding $1.2 million in research funding.

The six scientists are conducting basic and tumor immunology laboratory investigations at distinguished academic institutions throughout the United States, as well as in Greece and Japan. Areas of research under investigation within the investigators’ laboratories include immune cell signaling pathways, immuno-modulation and regulatory mechanisms, and genetic factors of immune cell development and function.

The CRI Investigator Award Program aids scientists who are newly embarking on their independent academic research careers at the assistant professor level. These awards are not tied to any specific research project. Rather, the awards provide researchers the freedom to pursue promising lines of inquiry that their new responsibilities otherwise might not allow them to follow. The aim of the program is to provide flexibility and a degree of stability in what is essentially a make-or-break period in the scientist’s life. Since the Investigator Award Program’s inception in 1986, 120 investigators have received funding from the Cancer Research Institute, including the newest winners.

June 2008 Investigator Award Recipients

• Hongbo Chi, Ph.D., at St. Jude Children’s Research Hospital, Memphis, Tennessee, is investigating how the MAPK protein pathway, a pathway essential for integrating signals from antigen and cytokine receptors, functions in dendritic cell-mediated immune responses and stimulation of anti-tumor immunity. His study may be translated into new therapeutic strategies for treating cancers and autoimmune diseases.

• Morgan Huse, Ph.D., at the Memorial Sloan-Kettering Cancer Center, New York, New York, is studying how natural killer cells receive inhibitory and activating signals to induce natural killing responses to cancerous cells. Developing an understanding of natural killer cell mechanisms advances strategies to modulate their activity to better fight cancer.

• Hiroyoshi Nishikawa, M.D., Ph.D., at the University Graduate School of Medicine, Tsu, Mie, Japan, is clarifying questions of how regulatory T cells (Tregs) suppress immune responses by identifying which antigens are recognized by Tregs. This knowledge would provide an important next step to avoid undesired activation of Tregs by cancer vaccines aimed at inducing CD4+ Th helper cell-dependent development of antibodies.

• Neetu Gupta, Ph.D., at the Cleveland Clinic Foundation, Cleveland, Ohio, is enhancing the current understanding of B-cell activation, a process critical to antibody production. She is studying a protein called ezrin, which facilitates the B-cell response by participating in signal communication. Ultimately, this research promises a better comprehension of immunological diseases that result from interruption of signaling pathways and cellular architecture, and would enable identification of drug targets for specific and smarter therapy.

• Charalampos Spilianakis, Ph.D., at the Foundation of Research and Technology – Hellas (FORTH), Crete, Greece, is characterizing the protein complexes that generate and/or maintain interchromosomal interactions to understand how the genome is shaped and how the nuclear structure affects global gene expression. His research could lead to new insight into the link between the physical proximity of genomic loci and the increased probability of chromosomal translocations (mutations) and how these can lead to the creation of cancerous malignancies.

• Russell E. Vance, Ph.D., at the University of California, Berkeley, Berkeley, California, is addressing the fundamental question of how the immune system initially distinguishes normal from abnormal tissue by studying how a gene called Naip5 regulates the innate immune response. This understanding could help develop Naip5-related therapeutics that will stimulate innate immune responses against pathogenic intruders or tumors in cases when the immune system has inappropriately ignored these dangers.

More detailed descriptions of the investigators’ research can be viewed at http://www.cancerresearch.org/programs/research/investigator-award/investigators-2008-06.html. CRI extends its congratulations to each of this year’s award recipients. The next deadline for Investigator Award applications is March 1, 2009.

About the Cancer Research Institute
The Cancer Research Institute (CRI) is the world’s only non-profit organization dedicated exclusively to the support and coordination of scientific and clinical efforts that will lead to the immunological treatment, control, and prevention of cancer. Guided by a world-renowned Scientific Advisory Council that includes five Nobel Prize winners and thirty members of the National Academy of Sciences, CRI supports cutting-edge cancer research at top medical centers and universities throughout the world. The Cancer Research Institute is ushering in a new era of scientific progress, hastening the discovery of effective cancer vaccines and other immune-based therapies that are providing new hope to cancer patients.

The Cancer Research Institute has one of the lowest overhead expense ratios among non-profit organizations, with the majority of its resources going directly to the support of its science, medical, and research programs. This has consistently earned CRI an A grade or higher for fiscal disclosure and efficiency from the American Institute of Philanthropy and top marks from other charity watchdog organizations. http://www.cancerresearch.org

Brian Brewer | Newswise Science News
Further information:
http://www.cancerresearch.org

More articles from Awards Funding:

nachricht The quest for the oldest ice on Earth
14.11.2016 | Alfred-Wegener-Institut, Helmholtz-Zentrum für Polar- und Meeresforschung

nachricht Empa Innovation Award for new flame retardant
09.11.2016 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt

All articles from Awards Funding >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Predicting unpredictability: Information theory offers new way to read ice cores

07.12.2016 | Earth Sciences

Sea ice hit record lows in November

07.12.2016 | Earth Sciences

New material could lead to erasable and rewriteable optical chips

07.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>